Return to Special Authority drug list
Generic name |
risankizumab |
|
Strength & form |
360 mg/2.4 mL pre-filled, single-use cartridge with on-body injector 600 mg/10 mL single-use vial |
Special Authority criteria |
Approval period |
---|---|
InitialModerately to severely active Crohn's disease For the treatment of adult patients with moderately to severely active Crohn's disease when ALL of the following criteria are met:
AND
AND
Fistulizing Crohn's disease For the treatment of adult patients with active fistulizing Crohn's disease when ALL of the following criteria are met:
AND
|
16 weeks |
RenewalModerately to severely active Crohn's disease For the continued treatment of adult patients with moderately to severely active Crohn's disease when ALL of the following criteria are met:
AND
Fistulizing Crohn's disease For the continued treatment of adult patients with active fistulizing Crohn's disease when ALL of the following criteria are met:
AND
|
1 year |